Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers

Journal of Clinical Psychopharmacology

Volumn 21, Issue 2, 2001, Pages 161-166

  Harvey, Anne T ^a,b   Preskorn, Sheldon H ^a,b  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; FLUOXETINE; MEPHENYTOIN; NORFLUOXETINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FLUOXETINE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; SEROTONIN UPTAKE INHIBITORS;

EID: 0035103586     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200104000-00007     Document Type: Article

References (27)

1. Evolutionary trends in the pharmacotherapeutic management of depression
2. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
3. The pharmacokinetics of paroxetine in the elderly
4. A pharmacokinetic dose titration study in adult and elderly depressed patients
5. Kinetics of citalopram in elderly patients
6. A review of the metabolism and pharmacokinetics of paroxetine in man
7. The pharmacokinetics of paroxetine in elderly depressed patients
8. Fluoxetine: Clinical pharmacology and physiologic disposition
9. Clinical pharmacokinetics of fluoxetine
10. Clinical pharmacology and pharmacokinetics of fluoxetine: A review
11. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
12. Influence of fluoxetine on plasma levels of desipramine
13. Detectable levels of fluoxetine metabolites after discontinuation: An unexpected serotonin syndrome
14. Cytochrome P450 isozymes and antiepileptic drug interactions
15. From the Food and Drug Administration. Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers
16. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
17. Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography
18. Determination of dextromethorphan and metabolites in human plasma and urine by high-performance liquid chromatography with fluorescence detection
19. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study
20. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
21. Targeted pharmacotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine and sertraline
22. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome
23. Inhibition by fluoxetine of cytochrome P450 2D6 activity
24. The prevalence of polypharmacy as a potential risk for drug interactions in the outpatient treatment of major depression and the inpatient treatment of schizophrenia
25. Human cytochromes mediating N-demethylation of fluoxetine in vitro
26. The effects of selective serotonin reuptake inhibitors and their metabolites on s-mephenytoin 4′-hydroxylase activity in human liver microsomes